<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.02725.031</object-id><label>Table 2.</label><caption><p>Pathways most significantly affected by exonic indels</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02725.031">http://dx.doi.org/10.7554/eLife.02725.031</ext-link></p><p><supplementary-material id="SD9-data"><object-id pub-id-type="doi">10.7554/eLife.02725.032</object-id><label>Table 2&#8212;source data 1.</label><caption><title>Results of pathway enrichments, custom definition of the DSBR by HR pathway and the allelic frequencies of mutations in HR genes.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02725.032">http://dx.doi.org/10.7554/eLife.02725.032</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-02725-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center">Database</th><th align="center">Pathway</th><th align="center">Rank</th><th align="center">FDR</th><th align="center">Affected samples (n = 16)</th><th align="center">Mutations per sample</th></tr></thead><tbody><tr><td/><td><xref ref-type="table-fn" rid="tblfn2">*</xref>DSBR by HR (custom definition)</td><td>n.a.</td><td>n.a.</td><td align="char" char=".">16</td><td align="char" char=".">3.25</td></tr><tr><td rowspan="5">BioCarta (ranking by GenomeMusic)</td><td><xref ref-type="table-fn" rid="tblfn2">*</xref>ATR/BRCA pathway</td><td align="char" char=".">1</td><td>1.0E&#8722;16</td><td align="char" char=".">15</td><td align="char" char=".">3.50</td></tr><tr><td>ATM pathway</td><td align="char" char=".">2</td><td>5.9E&#8722;11</td><td align="char" char=".">15</td><td align="char" char=".">2.69</td></tr><tr><td>G2 pathway</td><td align="char" char=".">3</td><td>7.2E&#8722;08</td><td align="char" char=".">15</td><td align="char" char=".">2.81</td></tr><tr><td>IL10 pathway</td><td align="char" char=".">4</td><td>2.2E&#8722;05</td><td align="char" char=".">12</td><td align="char" char=".">1.75</td></tr><tr><td>CARM1 and regulation of the Estrogen Receptor pathway</td><td align="char" char=".">5</td><td>2.2E&#8722;05</td><td align="char" char=".">14</td><td align="char" char=".">3.19</td></tr><tr><td rowspan="4">DNA Repair DB (ranking by GenomeMusic)</td><td><xref ref-type="table-fn" rid="tblfn2">*</xref>Homologous recombination pathway</td><td align="char" char=".">1</td><td>1.3E&#8722;04</td><td align="char" char=".">13</td><td align="char" char=".">1.56</td></tr><tr><td>Base excision repair pathway</td><td align="char" char=".">2</td><td>9.0E&#8722;02</td><td align="char" char=".">10</td><td align="char" char=".">0.75</td></tr><tr><td>Non-homologous end joining pathway</td><td align="char" char=".">3</td><td>1.7E&#8722;01</td><td align="char" char=".">9</td><td align="char" char=".">0.69</td></tr><tr><td>Nucleotide excision repair pathway</td><td align="char" char=".">4</td><td>8.3E&#8722;01</td><td align="char" char=".">7</td><td align="char" char=".">0.50</td></tr><tr><td rowspan="8">Reactome (ranking by GenomeMusic)</td><td>DNA repair</td><td align="char" char=".">1</td><td>2.5E&#8722;11</td><td align="char" char=".">15</td><td align="char" char=".">6.69</td></tr><tr><td>Double strand break repair</td><td align="char" char=".">2</td><td>7.2E&#8722;08</td><td align="char" char=".">15</td><td align="char" char=".">2.94</td></tr><tr><td><xref ref-type="table-fn" rid="tblfn2">*</xref>Homologous recombination repair</td><td align="char" char=".">3</td><td>1.9E&#8722;07</td><td align="char" char=".">15</td><td align="char" char=".">2.31</td></tr><tr><td>G2/M checkpoints</td><td align="char" char=".">4</td><td>2.3E&#8722;07</td><td align="char" char=".">15</td><td align="char" char=".">3.50</td></tr><tr><td>Cell cycle checkpoints</td><td align="char" char=".">5</td><td>4.5E&#8722;05</td><td align="char" char=".">15</td><td align="char" char=".">4.75</td></tr><tr><td>Base excision repair</td><td align="char" char=".">15</td><td>8.3E&#8722;03</td><td align="char" char=".">10</td><td align="char" char=".">0.94</td></tr><tr><td>Non-homologous end joining</td><td align="char" char=".">59</td><td>1.0E+00</td><td align="char" char=".">8</td><td align="char" char=".">0.63</td></tr><tr><td>Nucleotide excision repair</td><td align="char" char=".">61</td><td>5.9E&#8722;01</td><td align="char" char=".">10</td><td align="char" char=".">1.50</td></tr><tr><td rowspan="6">IPA (ranking by IPA)</td><td><xref ref-type="table-fn" rid="tblfn2">*</xref>DNA double-strand break repair by homologous recombination</td><td align="char" char=".">1</td><td>4.7E&#8722;03</td><td align="char" char=".">15</td><td align="char" char=".">1.56</td></tr><tr><td>Ovarian cancer signaling</td><td/><td>4.7E&#8722;03</td><td align="char" char=".">16</td><td align="char" char=".">5.75</td></tr><tr><td>Role of NFAT in cardiac hypertrophy</td><td align="char" char=".">3</td><td>6.8E&#8722;03</td><td align="char" char=".">14</td><td align="char" char=".">3.88</td></tr><tr><td>Cell cycle: G2/M DNA damage checkpoint regulation</td><td align="char" char=".">4</td><td>1.3E&#8722;02</td><td align="char" char=".">15</td><td align="char" char=".">2.88</td></tr><tr><td>PPAR&#945;/RXR&#945; activation</td><td align="char" char=".">5</td><td>1.4E&#8722;02</td><td align="char" char=".">15</td><td align="char" char=".">4.63</td></tr><tr><td>DNA double-strand break repair by non-homologous end joining</td><td align="char" char=".">60</td><td>1.7E&#8722;01</td><td align="char" char=".">14</td><td align="char" char=".">1.50</td></tr></tbody></table><table-wrap-foot><fn><p>The five top ranking pathways are listed, as well as all annotated pathways relevant for DNA repair. The custom definition used throughout this manuscript was added for illustrative purposes. n.a. = not applicable.</p></fn><fn id="tblfn2"><label>*</label><p>The DSBR by HR pathway.</p></fn></table-wrap-foot></table-wrap>